Home
About
Overview
Sharing Data
ORCID
Help
History (0)
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Ratain, Mark J.
One or more keywords matched the following items that are connected to
Ratain, Mark J.
Item Type
Name
Concept
Clinical Trials, Phase I as Topic
Concept
Clinical Trials, Phase II as Topic
Concept
Clinical Trials, Phase III as Topic
Academic Article
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
Academic Article
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
Academic Article
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
Academic Article
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
Academic Article
Data modifications to phase I study of suramin.
Academic Article
New phase I trial methodology.
Academic Article
Learning from our patients: one participant's impact on clinical trial research and informed consent.
Academic Article
Study of cohort-specific consent and patient control in phase I cancer trials.
Academic Article
Promising new agents in oncologic treatment.
Academic Article
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
Academic Article
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
Academic Article
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
Academic Article
Endostatin: are the 2 years up yet?
Academic Article
Troxacitabine in patients with refractory leukemia.
Academic Article
Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs.
Academic Article
Phase II oncology trials: let's be positive.
Academic Article
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
Academic Article
Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
Academic Article
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
Academic Article
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
Academic Article
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Academic Article
EGFR pharmacogenomics: the story continues to mutate and evolve.
Academic Article
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Academic Article
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
Academic Article
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Academic Article
Evaluating the activity of temsirolimus in neuroendocrine cancer.
Academic Article
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
Academic Article
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?
Academic Article
Optimising the design of phase II oncology trials: the importance of randomisation.
Academic Article
Prognostic factors for survival in patients treated in phase I clinical trials.
Academic Article
Resampling phase III data to assess phase II trial designs and endpoints.
Academic Article
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Academic Article
Randomized phase II trials: a long-term investment with promising returns.
Academic Article
Pushing the envelope: informed consent in phase I trials.
Academic Article
Dose-escalation models for combination phase I trials in oncology.
Academic Article
Analysis of the yield of phase II combination therapy trials in medical oncology.
Academic Article
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?
Academic Article
Perceptions of cancer patients and their physicians involved in phase I trials.
Academic Article
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.
Academic Article
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
Academic Article
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
Academic Article
Targeted therapies: redefining the primary objective of phase I oncology trials.
Academic Article
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Academic Article
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.
Academic Article
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
Academic Article
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).
Academic Article
Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.
Academic Article
Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.
Academic Article
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
Academic Article
Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.
Academic Article
Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?
Academic Article
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Search Criteria
Clinical Trials Phase IV as Topic